# A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

> **NCT02740985** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 313 (actual)

## Conditions studied

- Advanced Solid Malignancies
- Non-Small Cell Lung Cancer (NSCLC)
- Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)
- Colorectal Carcinoma (CRC)

## Interventions

- **DRUG:** AZD4635
- **DRUG:** Durvalumab
- **DRUG:** Abiraterone Acetate
- **DRUG:** Enzalutamide
- **DRUG:** Oleclumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02740985
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-17
- **Primary completion:** 2020-12-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 313 (ACTUAL)
- **Last updated:** 2023-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02740985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02740985, "A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02740985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*